Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.

MLA

Zhang, Wenjing, et al. “Mutations in DNA Damage Response Pathways as a Potential Biomarker for Immune Checkpoint Blockade Efficacy: Evidence from a Seven-Cancer Immunotherapy Cohort.” Aging, vol. 13, no. 21, Nov. 2021, pp. 24136–54. EBSCOhost, https://doi.org/10.18632/aging.203670.

APA

Zhang, W., Zhang, L., Jiang, H., Li, Y., Wang, S., & Wang, Q. (2021). Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort. Aging, 13(21), 24136–24154. https://doi.org/10.18632/aging.203670

Chicago

Zhang, Wenjing, Liwen Zhang, Hao Jiang, Yuting Li, Suzhen Wang, and Qinghua Wang. 2021. “Mutations in DNA Damage Response Pathways as a Potential Biomarker for Immune Checkpoint Blockade Efficacy: Evidence from a Seven-Cancer Immunotherapy Cohort.” Aging 13 (21): 24136–54. doi:10.18632/aging.203670.